News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
FDA
FDA Issues Health Advisory on Pfizer Inc.'s Chantix Tablets
February 1, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
WASHINGTON -- The Food and Drug Administration said it is "increasingly likely" that Pfizer Inc.'s smoking-cessation drug Chantix may be tied to serious psychiatric symptoms. The FDA's comment is part of a public health advisory issued Friday.
Twitter
LinkedIn
Facebook
Email
Print
FDA
Approvals
Pfizer
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Regulatory
Summit’s Potential Keytruda Rival Gets November FDA Decision Date
January 30, 2026
·
1 min read
·
Tristan Manalac
Insights
Biotech’s Next Chapter: Asset-Centric Deals and Shifting Alpha at JPM 2026
January 29, 2026
·
3 min read
·
Jennifer Smith-Parker
Rare diseases
REGENXBIO Delay Could Put Denali in Pole Position for Hunter Syndrome Approval
January 28, 2026
·
2 min read
·
Dan Samorodnitsky
Cancer
J&J’s Darzalex Faspro Notches Another Multiple Myeloma Indication, Pushing Into Frontline
January 28, 2026
·
2 min read
·
Tristan Manalac